Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Osteoporosis is a bone related disease that weakens bones and increase the risk of fracture and breaking of bones. The factors responsible for osteoporosis include, long-term use of high-dose oral corticosteroids, a family history of osteoporosis – particularly history of a hip fracture in a parent, having a low body mass index (BMI), heavy drinking and smoking, and others. The prevalence of osteoporosis is high among the adult population. For instance, according to a report by National Osteoporosis Foundation in 2016, around 54 million adult in the U.S were suffering from osteoporosis or have low bone density.
Market Dynamics
Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over forecast period. For instance, in 2013, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for its drug— DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets—for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. Furthermore, osteoporosis commonly affects older adults and increasing geriatric population is expected to lead to high demand for osteoporosis treatment drugs. For instance, according to a report by United Nations Population Fund, people aged 60 years and above accounted for 12.3% of the global population in 2015 and this is expected to reach 22% by 2050 that accounts for 2 billion people.
Key features of the study:
This report provides in-depth analysis of the osteoporosis treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global osteoporosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
Key companies covered as a part of this study include, EffRx Pharmaceuticals SA, Daiichi Sankyo Company, Limited, Amgen Inc., Dr Reddy\'s Laboratories, Mylan Inc., Pfenex Inc., Eli Lilly and Company, Asahi Kasei Corporation, F.Hoffmann La Roche, Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co AG, GlaxoSmithKline Plc., Allergan plc., and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technological up-gradation, market expansion, and marketing tactics
The global osteoporosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the osteoporosis treatment market
Detailed Segmentation:
Global Osteoporosis Treatment Market, by Drug Type :
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
Global Osteoporosis Treatment Market, by Route of Administration:
Oral
Injectable
Others
Global Osteoporosis Treatment Market, by Distribution Channel:
Hospitals
Online Pharmacies
Retail Pharmacies
Global Osteoporosis Treatment Market, by Geography:
North America
Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration:
Oral
Injectable
Others
By Distribution Channel
Hospitals
Online Pharmacies
Retail Pharmacies
By Country:
U.S.
Canada
Europe
Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration:
Oral
Injectable
Others
By Distribution Channel
Hospitals
Online Pharmacies
Retail Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration:
Oral
Injectable
Others
By Distribution Channel
Hospitals
Online Pharmacies
Retail Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration:
Oral
Injectable
Others
By Distribution Channel
Hospitals
Online Pharmacies
Retail Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration:
Oral
Injectable
Others
By Distribution Channel
Hospitals
Online Pharmacies
Retail Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration:
Oral
Injectable
Others
By Distribution Channel
Hospitals
Online Pharmacies
Retail Pharmacies
By Country:
Central Africa
South Africa
North Africa
Company Profiles
Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Daiichi Sankyo Company Limited.
Amgen Inc.
Dr Reddy\'s Laboratories
Mylan Inc.
Pfenex Inc.
Eli Lilly and Company
Asahi Kasei Corporation
F.Hoffmann La Roche
EffRx Pharmaceuticals SA
Novartis AG
Merck & Co AG
GlaxoSmithKline Plc.
Allergan plc.
Pfizer Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Drug Type
o Market Snippet, By Route of Administration
o Market Snippet, By Distribution Channel
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o PEST Analysis
o Pipeline Analysis
o Product Approval
o Product Launch
o Collaboration-Acquisition
o Porter's Five Forces Analysis
4. Global Osteoporosis Treatment Market, By Drug Type, 2016 - 2026 (US$ Bn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Bisphosphonates
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Segment Trends
o Alendronate
o Risedronate
o Ibandronate
o Zoledronic Acid
o Others
o Calcitonin
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Hormone Therapy
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Selective Estrogen Receptor Modulators (SERMs)
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Parathyroid Hormone-Related Protein (PTHrP) Analog
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Rank Ligand (RANKL) Inhibitor
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
5. Global Osteoporosis Treatment Market, By Route of Administration, 2016 - 2026 (US$ Bn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Oral
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Injectable
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
6. Global Osteoporosis Treatment Market, By Distribution Channel, 2016 - 2026 (US$ Bn)
o Introduction
o Market Share Analysis, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Hospitals
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Online Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
o Retail Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Bn)
7. Global Osteoporosis Treatment Market, By Region, 2016 - 2026 (US$ Bn)
o Introduction
o Market Share Analysis, By Region, 2018 and 2026 (%)
o Y-o-Y Growth Analysis, For Regions, 2017-2026
o North America
o Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
o U.S.
o Canada
o Europe
o Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Latin America
o Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Africa
o Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
o Central Africa
o South Africa
o North Africa
o Middle East
o Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Bn)
o Market Size and Forecast, By Country, 2016 - 2026 (US$ Bn)
o GCC
o Israel
o Rest of Middle East
8. Competitive Landscape
o Heat Map Analysis
o Company Profiles
o Teva Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Daiichi Sankyo Company Limited.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Amgen Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Dr Reddy's Laboratories
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Mylan Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Pfenex Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Eli Lilly and Company
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Asahi Kasei Corporation
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o F.Hoffmann La Roche
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o EffRx Pharmaceuticals SA
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Novartis AG
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Merck & Co AG
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o GlaxoSmithKline Plc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Allergan plc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
o Pfizer Inc.
o Company Overview
o Product Portfolio
o Key Developments
o Financial Performance
o Strategies
9. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 32 market data tables and 30 figures on "Osteoporosis Treatment Market - Global forecast to 2026".
